Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics, Inc. (Nasdaq: VERA) is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases, with a particular emphasis on autoimmune kidney disorders such as immunoglobulin A nephropathy (IgAN). The VERA news page on Stock Titan aggregates company press releases and third-party coverage so readers can follow key clinical, regulatory, and corporate developments affecting the stock.
News about Vera Therapeutics frequently centers on its lead product candidate, atacicept, an investigational fusion protein targeting BAFF and APRIL. Recent announcements include submission and U.S. FDA Priority Review of a Biologics License Application for atacicept in adults with IgAN, supported by data from the ORIGIN Phase 2b and ORIGIN 3 Phase 3 trials. The company has highlighted statistically significant and clinically meaningful reductions in proteinuria and a safety profile described as comparable to placebo, as well as presentations at major scientific meetings and publication of trial results in The New England Journal of Medicine.
Investors and followers of VERA stock can also expect news on pipeline expansion and broader immunology programs. Vera Therapeutics reports ongoing evaluation of atacicept in expanded IgAN populations and other autoimmune kidney diseases, along with development of VT-109, a next-generation BAFF/APRIL-targeting fusion protein licensed from Stanford University, and MAU868, a monoclonal antibody designed to neutralize BK virus infection in kidney transplant recipients.
In addition, the news flow includes capital markets and corporate updates, such as underwritten public offerings of Class A common stock, at-the-market sales agreements, inducement equity grants under the company’s 2024 Inducement Plan, and changes in board composition or executive roles disclosed via Form 8-K. Vera Therapeutics also announces participation in healthcare and investor conferences, where its management team presents clinical data and corporate strategy.
By reviewing the VERA news page regularly, readers can track how clinical milestones, regulatory decisions, financing activities, and governance changes may relate to Vera Therapeutics’ development programs and its position as a late clinical-stage biotech issuer.
Vera Therapeutics (Nasdaq: VERA) has announced an in-person and virtual R&D Day on October 2, 2024, in New York. The event will focus on potential indication expansion for atacicept, their lead drug candidate. Notable experts, including Dr. Jonathan Barratt, Dr. Richard Lafayette, and Dr. Brad Rovin, will join Vera's management team to discuss expanded atacicept R&D activities.
This event precedes the anticipated 96-week data from the Phase 2b ORIGIN study of atacicept in immunoglobulin A nephropathy (IgAN), scheduled for presentation at a medical congress in Q4 2024. Notably, atacicept has received FDA Breakthrough Therapy Designation for IgAN treatment, indicating its potential for substantial improvement over existing therapies based on Phase 2b ORIGIN trial data.
Vera Therapeutics (Nasdaq: VERA) has completed enrollment for the primary endpoint in its pivotal Phase 3 ORIGIN 3 trial of atacicept in IgA Nephropathy (IgAN) patients. The trial enrolled 200 participants, with topline results expected in Q2 2025. The company plans to present 96-week data from the Phase 2b ORIGIN trial in Q4 2024. Atacicept has shown promising results in stabilizing kidney function and reducing hematuria, potentially transforming IgAN treatment. The FDA granted atacicept Breakthrough Therapy Designation earlier this year. Vera believes atacicept could be among the first B cell modulators approved for IgAN, offering a new foundation for treating this organ-threatening disease.
Vera Therapeutics (Nasdaq: VERA) announced inducement awards for two new employees on September 5, 2024. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4), include:
1. A non-qualified stock option to purchase 21,750 shares of Class A common stock
2. Restricted stock units (RSUs) for 9,875 shares of Class A common stock
The stock option has an exercise price of $38.16 per share, based on Vera's closing price on September 5, 2024. It will vest over four years, with 25% vesting on the first anniversary and the remainder monthly over 36 months. The RSUs will vest over four years, with 25% vesting annually starting November 20, 2024. Both awards are subject to continued employment and the terms of the Inducement Plan and award agreements.
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotech company, announced its participation in two investor conferences in September 2024. The company, which focuses on developing treatments for serious immunological diseases, will attend:
1. Wells Fargo Healthcare Conference on September 5 in Boston, MA, participating in one-on-one meetings.
2. Cantor Global Healthcare Conference on September 18 in New York, NY, featuring a fireside chat at 9:10am EDT and one-on-one meetings.
A webcast of the Cantor conference presentation will be available, with a 90-day replay accessible on Vera Therapeutics' website in the 'Investor Calendar' section.
Vera Therapeutics (Nasdaq: VERA) has announced inducement awards for three new employees, approved by the Compensation Committee on August 6, 2024. The awards include:
1. A non-qualified stock option to purchase 33,000 shares of Class A common stock
2. Restricted stock units (RSUs) for 16,500 shares of Class A common stock
The stock option has an exercise price of $37.44 per share, equal to Vera's closing trading price on August 6, 2024. Both the stock options and RSUs will vest over four years, with specific vesting schedules. These awards are subject to the terms and conditions of the Inducement Plan and applicable award agreements.
Vera Therapeutics (VERA) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. FDA granted Breakthrough Therapy Designation for atacicept in IgA Nephropathy (IgAN).
2. Presented Phase 2b ORIGIN study data at ERA24 Congress, showing atacicept stabilized kidney function through 72 weeks.
3. Topline 96-week data from Phase 2b ORIGIN study expected in Q4 2024.
4. On track to complete enrollment in pivotal Phase 3 ORIGIN 3 trial in Q3 2024; topline data expected in Q2 2025.
5. Q2 2024 net loss of $33.7 million, or $0.62 per diluted share.
6. Cash position of $384.4 million as of June 30, 2024, believed sufficient to fund operations through approval and US commercial launch of atacicept, if approved.
Vera Therapeutics announced on July 5, 2024, that it has granted inducement awards under Nasdaq Listing Rule 5635(c)(4) to new employees, including the newly appointed COO, David Johnson. The grants, approved by the Compensation Committee, include non-qualified stock options to purchase 160,000 shares for Johnson and additional inducement awards of 139,100 stock options and 61,925 restricted stock units (RSUs) to ten new employees. The exercise prices for the stock options are $36.29 and $34.93, corresponding to the closing trading prices on the respective grant dates of July 1 and July 2, 2024. The options and RSUs will vest over four years, contingent upon continuous service. These awards are a strategic incentive to attract top talent to Vera Therapeutics.
Vera Therapeutics announced the immediate appointment of David L. Johnson as Chief Operating Officer. Johnson brings over 30 years of experience in the biopharmaceutical industry, including key roles at Global Blood Therapeutics and Gilead Sciences. He will oversee the commercialization efforts for atacicept, a treatment for IgAN, which is currently in Phase 2b and Phase 3 clinical trials. CEO Marshall Fordyce highlighted Johnson's expertise in successful commercial launches as important for the potential launch of atacicept. Johnson expressed enthusiasm for advancing atacicept, noting its promising clinical data and potential to be among the first approved B cell modulators for IgAN.
Vera Therapeutics has appointed Christy J. Oliger to its board of directors, effective June 7, 2024. Oliger brings over 30 years of experience in the biopharmaceutical industry, having led significant commercial product launches and built highly effective teams. She currently serves on the boards of Karyopharm Therapeutics, Replimune Group, and LAVA Therapeutics, and has past board experience with Sierra Oncology, Reata Pharmaceuticals, and RayzeBio. Oliger’s extensive experience will support Vera's advancement of atacicept for IgAN treatment and its potential commercial launch.
On June 4, 2024, Vera Therapeutics granted inducement awards to five new employees under its 2024 Inducement Plan. These awards include non-qualified stock options to purchase 31,250 shares of Class A common stock and restricted stock units (RSUs) for 14,500 shares. The stock options have an exercise price of $39.47 per share, matching Vera’s closing price on that date. The stock options and RSUs vest over four years with specific conditions attached. These grants were approved by Vera's Compensation Committee in adherence to Nasdaq Listing Rule 5635(c)(4) as an inducement for employment.
FAQ
What is the current stock price of Vera Therapeutics (VERA)?
What is the market cap of Vera Therapeutics (VERA)?
